Showing results (3051-3060 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|December 16, 1998
Phase II study of paclitaxel (BMS-181339) intravenously infused over 3 hours for advanced or metastatic breast cancer in Japan. BMS-181339 Breast Cancer Study GroupY Ito, N Horikoshi, T Watanabe, et al.
Investigational New Drugs|January 1, 1996
Clinical phase I and pharmacokinetic trial of vinorelbine administered as single intravenous bolus every 21 days in cancer patientsT Schilling, H H Fiebig, S Kerpel-Fronius, et al.
Investigational New Drugs|January 1, 1996
13-Cis-retinoic acid and interferon alpha-2a in patients with advanced esophageal cancer: a phase II trialC F Slabber, G Falkson, W Burger, et al.
Investigational New Drugs|August 31, 2025
Safety and efficacy of semi-dose venetoclax plus azacitidine in unfit acute myeloid leukemia patients in China: a real-world single-center studyXian Li, Xin-Yi Zhu, Xi-Bin Xiao, et al.
Investigational New Drugs|April 17, 2010
MT103 inhibits tumor growth with minimal toxicity in murine model of lung carcinoma via induction of apoptosisPiotr Jasinski, Pawel Zwolak, Rachel Isaksson Vogel, et al.
Investigational New Drugs|May 14, 2010
Apoptotic induction by simvastatin in human lung cancer A549 cells via Akt signaling dependent down-regulation of survivinKi-Eun Hwang, Kyoung-Suk Na, Do-Sim Park, et al.
Investigational New Drugs|March 30, 2010
Phase I trial of oblimersen (Genasense®) and gemcitabine in refractory and advanced malignanciesPeter S Galatin, Ranjana H Advani, George A Fisher, et al.
Investigational New Drugs|August 21, 2008
Application of population pharmacokinetic modeling in early clinical development of the anticancer agent E7820Ron J Keizer, Miren K Zamacona, Mendel Jansen, et al.
Investigational New Drugs|May 1, 1991
Effects of isomeric 2-(arylmethylamino)-1,3-propanediols (AMAPs) and clinically established agents on macromolecular synthesis in P388 and MCF-7 cellsC A Carter, K W Bair
Investigational New Drugs|May 1, 1991
A novel N-myristylated synthetic octapeptide inhibits protein kinase C activity and partially reverses murine fibrosarcoma cell resistance to adriamycinC A O'Brian, N E Ward, R M Liskamp, et al.
Pageof 372